TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
GMAB

Genmab AS

Healthcare · Biotechnology

35.40$ +0.1% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Income Statement

Genmab AS (GMAB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 3,723 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement GMAB
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
850 1,133 1,816 2,365 3,025 5,366 10,111 8,417 14,505 16,474 21,526 3,723
– 0.0 0.0 0.0 0.0 0.0 – 0.0 0.0 226 985 309
850 1,133 1,816 2,365 3,025 5,366 10,111 8,417 14,505 16,248 20,541 3,414
506 488 661 874 1,431 2,386 3,137 4,181 5,562 7,630 9,748 1,560
80 91 102 147 214 342 661 1,283 2,676 3,297 3,790 626
585 403 763 1,021 1,645 2,728 3,798 5,464 8,238 10,927 13,838 2,163
265 730 1,053 1,344 1,380 2,638 6,313 2,953 6,267 5,321 6,703 1,251
4.1 0.1 0.2 2.0 0.4 7.0 10 13 21 27 120 61
297 758 1,130 1,064 1,612 2,859 5,904 3,918 6,945 5,637 9,164 1,205
-4.0 -6.0 -57 -40 140 693 1,146 961 1,493 1,285 1,320 241
301 764 1,187 1,104 1,472 2,166 4,758 2,957 5,452 4,352 7,844 964
314 789 1,171 1,488 1,700 3,005 6,160 4,181 7,346 5,947 9,697 1,337

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?